Top View
- Decitabine in Myelodysplastic Syndromes
- Chidamide, Decitabine, Cytarabine, Aclarubicin, and Granulocyte Colony
- Cancer Drug Costs for a Month of Treatment at Initial Food
- Novel Drugs for Older Patients with Acute Myeloid Leukemia
- FDA-Approved Drugs Under Investigation in Multiple Myeloma for Actionable Targets
- Dual Roles of SAMHD1 in Tumor Development and Chemoresistance to Anticancer Drugs (Review)
- Subcutaneous Administration of Anticancer Agents
- Hydroxyurea [CAS No
- Epigenetic Cancer Therapy: Rationales, Targets and Drugs
- Treating Chronic Myelomonocytic Leukemia If You’Ve Been Diagnosed with Chronic Myelomonocytic Leukemia (CMML), Your Treatment Team Will Discuss Your Options with You
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Decitabine Versus 5-Azacitidine for the Treatment of Myelodysplastic Syndrome: Adjusted Indirect 1
- Phase 1B Study of IGF-Methotrexate Conjugate in the Treatment of High-Grade Myelodysplastic Syndromes HASSAN B
- Dacogen EMA Public Assessment Report
- Cardiotoxicity of Novel Targeted Hematological Therapies
- Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines Tai C Hun Q in , 1Emile M.Youssef,1Jaroslav Jelinek,1Rong Chen,1 Allen S
- 0975-8585 September–October 2016 RJPBCS 7(5) Page No
- The Effect of Decitabine Combined with Arsenic Trioxide on DAPK Gene and HL-60 Cell Proliferation and Apoptosis
- Emetogenic Potential of Antineoplastic Agents
- Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: a TACL Pilot Study Michael J
- AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
- Cladribine Combined with Low-Dose Cytarabine As Frontline Treatment
- Azacitidine Improves Antitumor Effects of Docetaxel and Cisplatin in Aggressive Prostate Cancer Models
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- List of Off-Patent, Off-Exclusivity Drugs Without an Approved Generic
- (Arsenic Trioxide) in the Treatment of Myelodysplastic Syndromes
- Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Acute Lymphoblastic Leukemia
- Decitabine Reverses CSC-Induced Docetaxel Resistance Via Epigenetic Regulation of DAB2IP in TNBC
- Study Protocol and Statistical Analysis Plan
- Combination of Decitabine, Idarubicin, Cytarabine, and G-CSF (DIAG) Regimen for the Treatment of High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia
- DACOGEN® (Decitabine) for Injection, for Intravenous Use Initial U.S
- Hypomethylating Chemotherapeutic Agents As Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
- DNA Methyltransferase Inhibitors Combination Therapy for The
- Decitabine Demonstrates Antileukemic Activity in B Cell Precursor Acute Lymphoblastic Leukemia with MLL Rearrangements C
- Blum, Et Al. V. Supergen, Inc., Et Al. 03-CV-1576-Complaint for Violation
- Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Decitabine Nanoparticles and Docetaxel Combination Shrinks Mammary Carcinoma Induced by DMBA in Female Sprague-Dawley Rats
- Cladribine in the Remission Induction of Adult Acute Myeloid Leukemia: Where Do We Stand?
- Altered DNA Methylation Is Associated with Docetaxel Resistance in Human Breast Cancer Cells
- Long-Lasting Reduction in Clonogenic Potential of Colorectal Cancer Cells
- Decitabine Monotherapy Induced Complete Molecular Response in A
- Low Doses of Decitabine Improve the Chemotherapy Efficacy Against
- The Antimetabolites
- Investigating Mechanisms Determining Cancer Cell Sensitivity to Carfilzomib and Novel Strategies to Overcome Resistance
- Decitabine Combined with Medium-Dose Cytarabine in the Treatment of DEK/CAN-Positive Acute Myeloid Leukemia: a Case Report
- Resistance to Decitabine and 5-Azacytidine Emerges from Adaptive Responses of The
- HOPA News Volume 9, Issue 3
- Chronic Myelomonocytic Leukemia Gold Jubilee
- Novel Homobarringtonie‑Containing Therapy for the Treatment of Patients with Primary Acute Myeloid Leukemia That Are Resistant to Conventional Therapy
- Decitabine Monotherapy Induced Complete Molecular Response in A
- Omacetaxine Mepesuccinate
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- Hazardous Drug List
- A High-Throughput Screen of Pharmacologically Active Compounds for Inhibitors of UHRF1 Reveals Epigenetic Activity of Anthracycline Derivative Chemotherapeutic Drugs
- Hypomethylating Agents in the Treatment of Acute Myeloid Leukemia: a T Guide to Optimal Use ⁎ Valeria Santinia, Gert J
- Decitabine Response in Breast Cancer Requires Efficient Drug Processing and Is Not Limited by Multidrug Resistance
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML